Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for eliciting an ~~immune~~ antigen specific cytotoxic T cell response in a subject comprising

administering an immunogenically effective amount of a peptide or protein antigen comprising one or more T cell epitope(s) coordinately with a non-viral vector comprising a polynucleotide encoding at least one of a B7-1, B7-2, and B7-3 co-stimulatory molecule, wherein the non-viral vector and peptide or protein antigen are administered separately to closely adjacent sites.

2. (Original) The method of claim 1, wherein the peptide or protein antigen comprises a T cell epitope of a tumor antigen or viral antigen.

3-5. (Cancelled)

6. (Currently amended) A method for eliciting an ~~immune~~ antigen specific cytotoxic T cell response in a subject comprising

administering an immunogenically effective amount of a protein antigen comprising at least one T cell epitope coordinately with a non-viral vector comprising a polynucleotide encoding at least one of a B7-1, B7-2, and B7-3 co-stimulatory molecule, wherein the non-viral vector and protein antigen are administered separately to closely adjacent sites.

7. (Previously presented) The method of claim 2, wherein the viral antigen is selected from a hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV) or human papilloma virus (HPV) antigen.

8. (Original) The method of claim 7, wherein the peptide antigen comprises at least nine contiguous amino acids of a HPV antigenic protein.

9-10. (Cancelled)

11. (Previously presented) The method of claim 1, wherein the at least one co-stimulatory molecule is B7-1, or B7-2.

12. (Previously presented) The method of claim 11, wherein the at least one co-stimulatory molecule is B7-1.

13. (Cancelled)

14. (Previously presented) The method of claim 1, wherein the peptide antigen and non-viral vector are administered to the subject in a sequential vaccination protocol.

15. (Previously presented) The method of claim 1, wherein the peptide antigen and non-viral vector are administered to intradermal, subcutaneous, mucosal or intratumoral sites.

16. (Original) The method of claim 1, wherein the non-viral vector is selected from a RNA or DNA vector.

17. (Previously presented) The method of claim 1, wherein the non-viral vector comprises a naked DNA vector having the polynucleotide encoding the co-stimulatory molecule(s) operably linked to regulatory elements necessary for expression of the co-stimulatory molecule(s) in eukaryotic cells.

18-32. (Cancelled)